CurrentPremera BluecrossPolicy N/A

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Select Intra-Abdominal and Pelvic Malignancies

Defines medical necessity and investigational indications for cytoreductive surgery with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and documents required for prior authorization and review for affected individuals and providers.

Policy Summary

PayerPremera Bluecross

PolicyHyperthermic Intraperitoneal Chemotherapy (HIPEC) for Select Intra-Abdominal and Pelvic Malignancies

Policy CodePolicy N/A

Change TypeMinor editorial update (no material clinical changes)

Effective DateOct. 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of diagnosis, neoadjuvant therapy details, and surgical cytoreductive outcome (residual disease ≤10 mm) for HIPEC requests.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

2Medically necessary conditions

Stage IIIOvarian stage for HIPEC

<=10 mmOptimal cytoreduction threshold

96547/96548/96446HIPEC CPT codes listed

No NCDMedicare NCD

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

47–156 moReported PMP survival

Coverage Criteria for CRS + HIPEC

NCCN‑considered indications (ovarian cancer)

NCCN-considered indications (ovarian cancer) — scenarios in which HIPEC may be considered per NCCN guidance for ovarian / fallopian tube / primary peritoneal carcinoma.

HIPEC with cisplatin (100 mg/m2) may be considered at the time of interval debulking surgery for newly diagnosed stage III epithelial ovarian, fallopian tube, or primary peritoneal carcinoma when ALL of the following are met:

• The patient has newly diagnosed FIGO stage III disease.

• The patient received neoadjuvant systemic chemotherapy (typically platinum‑based) prior to interval cytoreductive surgery.

• Optimal cytoreduction (residual tumor nodules <10 mm) is achievable at the time of interval debulking surgery.

• The patient has adequate performance status and organ function to tolerate surgery and HIPEC.

HIPEC can also be considered (category 2B) for selected stage IV patients when there has been a favorable response to neoadjuvant therapy with resolution or resectability of extra‑abdominal disease (eg, resolved malignant pleural effusion) or for patients who are poor primary surgical candidates but demonstrate response or stable disease after neoadjuvant therapy.

Operational note: Use shared decision‑making that considers patient preferences, expected quality of life impact, and availability of experienced multidisciplinary care. Participation in clinical trials is encouraged.

Coverage boundary: HIPEC for ovarian cancer outside the settings described above (for example primary upfront cytoreduction without neoadjuvant chemotherapy, routine use in stage IIIC/IV without documented favorable response and resectability, or other ovarian settings not specified by NCCN) is considered investigational per this policy.

Coding and Billing

Covered CPT Codes / HIPEC and Intraperitoneal ChemotherapyCPT

96446	Chemotherapy administration into the peritoneal cavity via indwelling port or catheter
96547	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure; first 60 minutes
96548	Intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) procedure; each additional 30 minutes

Alternate/Unlisted Chemotherapy CPTCPT

96549

Unlisted chemotherapy procedure (used when temporary catheter or intraoperative delivery)

Policy coding updatesCPT

96547	CPT code added to policy (HIPEC-related)
96548	CPT code added to policy (HIPEC-related)

Optimal cytoreduction residual size — key threshold

Optimal cytoreduction residual sizeResidual tumor nodules of 10 mm or less in diameter (<= 10 mm)

Use for eligibilityRequired at time of interval debulking for stage III ovarian/fallopian tube cancer when considering HIPEC

Documentation noteMedical records should document that optimal cytoreduction (<=10 mm) is achievable at the time of interval debulking surgery

Provider Actions Authorization, Documentation, and Risks

Prior Authorization

Prior Authorization Required

Prior authorization is required for cytoreductive surgery (CRS) with intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC). Submit a prior authorization request before the scheduled procedure to confirm medical necessity and benefits coverage.

Required prior authorization for HIPEC and associated procedures
Include clinical rationale in the request (diagnosis, indication, and planned intraoperative chemotherapy agent)

Prior Authorization

CRS + HIPEC — Center Selection and Expertise

When requesting authorization for CRS+HIPEC in select patients (for example, pseudomyxoma peritonei, diffuse malignant peritoneal mesothelioma, or selected stage III ovarian/fallopian tube cancer at interval debulking), the procedure should be performed at experienced, high-volume centers. Documentation should demonstrate multidisciplinary evaluation and surgical expertise given the procedures morbidity and mortality risks.

Recommend evaluation and treatment at experienced/high-volume centers

Definitions and Key Terms

Complete cytoreduction

DefinitionNo visible disease after surgery

TermComplete cytoreduction

ContextUsed to describe surgical outcome where no macroscopic tumor remains following cytoreductive surgery

Optimal cytoreduction definition

DefinitionResidual tumor nodules measuring 10 mm or less in diameter

TermOptimal cytoreduction

Policy useRequired criterion for HIPEC consideration at interval cytoreductive surgery in stage III ovarian/fallopian tube cancer

Line of Therapy Specific Criteria

second-line | interval cytoreductive setting

Criteria for interval (post‑neoadjuvant) cytoreductive setting in ovarian cancer — all conditions below must be met for consideration of HIPEC:

Interval cytoreductive surgery setting for ovarian cancer: (1) Newly diagnosed stage III invasive epithelial ovarian or primary peritoneal cancer; (2) Individual is not eligible for primary cytoreductive surgery OR primary surgery was incomplete and the individual received 3 cycles of cis‑platinum and paclitaxel systemic neoadjuvant chemotherapy immediately prior to interval‑debulking surgery; (3) Optimal cytoreduction (residual tumor nodules <10 mm) is achievable at the time of interval debulking surgery<= 10 mm

This specifies perioperative HIPEC at the time of interval cytoreduction; use of HIPEC in other ovarian settings is considered investigational.

first-line

First‑line (initial management) considerations noted in evidence summaries:

HIPEC with interval debulking for stage III ovarian cancer:

Regimens and Agent-Specific Guidance

Regimen	Dose / Timing	Clinical context	Coverage status
HIPEC with cisplatin
Cisplatin 100 mg/m2 administered intraoperatively at the time of interval debulking
For patients with low-volume residual disease at interval cytoreductive surgery for stage III invasive epithelial ovarian or primary peritoneal cancer; may also be considered for selected stage IV patients with favorable response to neoadjuvant therapy
Covered when criteria met (per NCCN v.2.2025)

Regimen	ASCO finding	Implication for use / Coverage
Oxaliplatin-based HIPEC combined with cytoreductive surgery
ASCO recommends against CRS with oxaliplatin-based HIPEC because it results in worse adverse events and little or no survival benefit for metastatic colorectal cancer
Not covered / discouraged for this indication (safety/efficacy concern)

Regimen	Recommendation language	Coverage implication
HIPEC with cisplatin 100 mg/m2 (single intraoperative administration)
"HIPEC with cisplatin (100 mg/m2) can be considered at the time of interval debulking surgery for stage III disease." (NCCN v.2.2025)
Covered for selected stage III ovarian/primary peritoneal cancer patients at interval debulking when documentation meets policy criteria

Background and Rationale

Cytoreductive surgery (CRS) aims to remove visible intra-abdominal tumor deposits (peritonectomy and multivisceral resections as needed). Hyperthermic intraperitoneal chemotherapy (HIPEC) refers to intraoperative instillation and recirculation of heated chemotherapy within the peritoneal cavity immediately following CRS to increase local drug exposure and exploit heat-enhanced cytotoxicity. HIPEC is proposed particularly for peritoneal surface malignancies such as pseudomyxoma peritonei and diffuse malignant peritoneal mesothelioma, where cohort data suggest substantial survival gains when combined with complete cytoreduction.

Evidence Summary and Guideline References

Evidence summaries vary by tumor type. For colorectal peritoneal carcinomatosis, RCTs and meta-analyses provide mixed results—some indicate survival benefit while at least one recent RCT showed no benefit and higher short-term adverse events. For gastric peritoneal carcinomatosis, small RCTs and meta-analyses report variable short-term survival benefits but heterogeneity and small sample sizes leave the evidence inconclusive. For ovarian cancer, RCTs and systematic reviews support HIPEC in the specific setting of newly diagnosed stage III disease after neoadjuvant chemotherapy at interval cytoreduction, with improved recurrence-free interval and reduced mortality; however, evidence for recurrent stage IIIC/IV ovarian disease is conflicting and insufficient to support routine use.

The policy’s coverage conclusions are evidence-based and tumor-specific: for pseudomyxoma peritonei and diffuse malignant peritoneal mesothelioma, cohort studies and systematic reviews report prolonged median and 5-year survival supporting medical necessity. For newly diagnosed stage III ovarian cancer after neoadjuvant chemotherapy, RCTs and systematic reviews indicate benefit when HIPEC is added at interval cytoreduction. For colorectal, gastric peritoneal carcinomatoses and several other indications (including appendiceal goblet cell tumors and some recurrent ovarian disease), the evidence is limited, heterogeneous, or conflicting and is judged insufficient to determine net health benefit; these indications are considered investigational.

NCCN ovarian cancer guidance (v.2.2025) notes that patients with low-volume residual disease after cytoreduction are potential candidates for intraperitoneal chemotherapy and that HIPEC with cisplatin (100 mg/m2) can be considered at the time of interval debulking for stage III disease. NCCN also allows consideration of HIPEC in select stage IV patients with favorable response to neoadjuvant therapy or resolved/resectable extraperitoneal disease.

There is no Medicare national coverage determination for HIPEC. Additionally, several drugs used in HIPEC protocols (for example, mitomycin, oxaliplatin, carboplatin) are not FDA-approved for this indication, and multiple peritoneal lavage/perfusion systems have FDA 510(k) clearance only for warmed sterile fluid irrigation—not for chemotherapy delivery; the FDA has issued warnings when such devices are promoted for off-label use in HIPEC.

Revision History

2023-10-01annual_review

Annual review with literature update through June 15, 2023; references added and updated; policy statements unchanged.

2024-01-01coding_update

Coding update: added new CPT code 96547.

2024-10-01annual_review

Annual review with literature update through June 5, 2024; references and guideline references updated; added CPT code 96548 and removed unlisted code 96549.

Policy Summary

PayerPremera Bluecross

PolicyHyperthermic Intraperitoneal Chemotherapy (HIPEC) for Select Intra-Abdominal and Pelvic Malignancies

Policy CodePolicy N/A

Change TypeMinor editorial update (no material clinical changes)

Effective DateOct. 1, 2025

Next Review DateN/A

Key ActionObtain prior authorization with documentation of diagnosis, neoadjuvant therapy details, and surgical cytoreductive outcome (residual disease ≤10 mm) for HIPEC requests.

SourceLink

On This Page

Document multidisciplinary discussion and center/facility experience

Denial Risk

Selection and Center Expertise Risk

NCCN and guideline sources note significant morbidity/mortality associated with HIPEC and recommend limiting use to experienced centers and highly selected patients. Insufficient center experience or lack of documentation of expertise may be a basis for denial or redirection to an experienced facility.

Significant morbidity and mortality — consider only in experienced centers
Referral or evaluation at a high-volume center is recommended for candidacy assessment

Denial Risk

Device Off-Label Use Risk

Some perfusion/lavage devices cleared by the FDA are intended only for irrigation or warming and have not been cleared or approved to administer chemotherapy. Use of devices off-label to deliver chemotherapeutic agents for HIPEC may present regulatory and coverage risk. Document the device name, model, and intended use; note that FDA has warned manufacturers against marketing lavage devices for off-label chemotherapy administration.

Document device manufacturer and model if used intraoperatively
Be aware FDA has not cleared these devices to administer chemotherapy; off-label use may affect coverage

Documentation Required

Required Documentation for Medical Necessity

Submit complete clinical documentation to support medical necessity for HIPEC. The request should include the history and physical, relevant imaging, pathology reports, and detailed operative note (or planned operative approach). For interval debulking in ovarian/fallopian tube cancer, include records of neoadjuvant systemic therapy and documentation that optimal cytoreduction (<10 mm residual) is achievable.

History & physical supporting the diagnosis
Recent imaging documenting disease distribution and resectability
Pathology confirming diagnosis
Operative report or detailed planned operative approach
Documentation of neoadjuvant chemotherapy when applicable (e.g., 3 cycles cisplatin + paclitaxel)
Documentation that optimal cytoreduction (residual tumor <10 mm) is achievable

Billing Rule

Prior Authorization and Relevant CPT Codes

Coding and authorization requests should include the surgical CPT codes and HIPEC-specific codes when applicable. Expected HIPEC-related CPT codes include 96547 (first 60 minutes) and 96548 (each additional 30 minutes). If intraperitoneal chemotherapy via indwelling port/catheter is used in other contexts, consider CPT 96446. Include all anticipated procedure and anesthesia codes in the authorization request.

CPT 96547 Intraoperative HIPEC procedure; first 60 minutes
CPT 96548 Intraoperative HIPEC procedure; each additional 30 minutes
CPT 96446 Chemotherapy administration into the peritoneal cavity via indwelling port/catheter (when applicable)
Include anticipated primary surgery CPT(s) alongside HIPEC codes in the authorization

Note

Guideline-Informed Sequencing Considerations

Guideline-informed sequencing: follow guideline recommendations for sequencing systemic therapy and CRS/HIPEC. For newly diagnosed advanced ovarian cancer, consider neoadjuvant chemotherapy followed by interval cytoreductive surgery with HIPEC for selected stage III patients (shared decision-making recommended). For colorectal and gastric primaries, CRS with HIPEC is controversial; NCCN suggests CRS/IC/HIPEC only in experienced centers for limited peritoneal disease and consideration within clinical trials for higher PCI. Document prior systemic therapy response and the rationale for timing of surgery.

For ovarian cancer: consider HIPEC at interval debulking after appropriate neoadjuvant chemotherapy in selected stage III patients; use shared decision-making
For colorectal/gastric primaries: reserve CRS/HIPEC for selected patients at experienced centers; consider clinical trial enrollment for higher PCI
Include documentation of systemic therapy regimens, response, and timing relative to planned surgery

Perioperative intraperitoneal chemotherapy

DefinitionIntraperitoneal chemotherapy administered at the same operative session as cytoreductive surgery

Policy scopeThis policy addresses only perioperative intraperitoneal chemotherapy (same-session delivery), not postoperative port-based intraperitoneal chemotherapy

PurposeDelivered to increase local peritoneal drug exposure and treat residual microscopic disease after surgical cytoreduction

HIPEC (short)

Short definitionIntraoperative perfusion of heated chemotherapy to the peritoneal cavity

MechanismHeat is used to enhance cytotoxicity and increase tissue penetration of intraperitoneal chemotherapy

TimingPerformed intraoperatively, typically immediately after cytoreductive surgery

HIPEC (expanded)

Expanded definitionHeated instillation and recirculation of chemotherapeutic agents within the peritoneal cavity performed intraoperatively, typically after cytoreductive surgery, to increase local drug exposure and exploit heat-enhanced cytotoxicity

Typical agents/dose exampleNCCN cites HIPEC with cisplatin 100 mg/m2 at interval debulking for selected stage III ovarian cancer patients

Clinical intentAims to treat residual microscopic disease and improve local control following removal of visible tumor deposits

Peritoneal lavage/perfusion systems (FDA product code LGZ)

Device classPeritoneal lavage/perfusion systems (FDA product code LGZ) cleared via 510(k) for warmed physiologically compatible sterile solution irrigation/lavage and temperature control

LimitationThese devices have not received marketing approval or clearance to administer chemotherapy and are not cleared for HIPEC drug delivery

Regulatory noteFDA has issued warnings to manufacturers when such devices are marketed for off-label use in HIPEC

ExamplesCleared devices include Performer HT, Belmont Hyperthermia Pump, FluidSmart, Hang&Go PAC and others listed in FDA 510(k) summaries

In newly diagnosed stage III ovarian cancer patients who received neoadjuvant chemotherapy, addition of HIPEC at interval cytoreductive surgery increased time to recurrence and reduced mortality in RCTs and systematic reviews

Supported by available RCTs/systematic reviews in the neoadjuvant/interval context.

second-line

Second‑line (recurrent disease) considerations — evidence is mixed and conclusions are limited:

Recurrent ovarian cancer (second‑line): Some RCTs reported improved survival with CRS plus HIPEC for recurrent stage IIIC/IV ovarian cancer, but other trials did not show benefit; results are limited by baseline imbalances (e.g., completeness of cytoreduction) and are considered insufficient/conflicting

Interpret with caution; evidence does not conclusively support routine coverage in recurrent settings.

Peritoneal carcinomatosis from colorectal origin (second‑line disease contexts): Randomized trials and meta‑analyses provide mixed results — while some controlled studies reported survival benefit, at least one recent RCT found no survival advantage and higher adverse events with HIPEC; evidence is insufficient to determine net health outcome

ASCO guidance discourages oxaliplatin‑based HIPEC for colorectal peritoneal metastases due to adverse events and little or no survival benefit.

second-line | interval (post-neoadjuvant)

Interval debulking (post‑neoadjuvant) specification per NCCN guidance:

Interval debulking setting: HIPEC with cisplatin (100 mg/m2) can be considered at the time of interval debulking surgery for stage III disease after neoadjuvant chemotherapy; may be considered in selected stage IV patients with favorable response to neoadjuvant therapy or resolved/resectable extraperitoneal disease

NCCN v.2.2025; document regimen details (cisplatin 100 mg/m2) when submitting prior authorization.

2025-10-01annual_review

Annual review with literature update through June 2, 2025; references and guideline references updated; policy statements unchanged.

2026-03-18minor_updateLatest

Minor edits for clarity only; policy intent unchanged.